Cash Oxycodone Prescription from an Out-of-State Prescriber
At a Honolulu community pharmacy, a 34-year-old man presents a paper prescription for oxycodone 30 mg, quantity 120, dated yesterday and written by a Nevada physician. He says he is visiting family, left his bottle on the mainland, and wants to pay cash because his insurance is out of state. The pharmacist queries the Hawaii prescription drug monitoring program and sees three opioid fills in the last 45 days at three different pharmacies, including oxycodone 30 mg #90 filled 10 days ago by a Hawaii prescriber. The Nevada prescriber’s office is closed for the day. When told verification will take time, the patient becomes loud and says he will report the pharmacist for refusing to fill a valid prescription. The pharmacy’s policy is to check the PMP for every opioid fill and to resolve red flags before dispensing. The pharmacist must decide whether to fill now, what to document, and whether any report is required.
1. May the pharmacist fill the prescription now? Explain the federal corresponding-responsibility standard and the specific red flags in this fact pattern.
Read the worked answer
No. A facially valid prescription is not enough. Under 21 CFR 1306.04(a), the pharmacist has a corresponding responsibility to ensure the prescription is issued for a legitimate medical purpose in the usual course of professional practice. The pharmacist must resolve red flags before dispensing.
Red flags here include:
- Out-of-state prescriber with an office that cannot be reached for verification.
- Cash payment for a large opioid quantity.
- Early refill: the PMP shows #90 filled 10 days ago, which is well short of a 30-day supply.
- Multiple prescribers and pharmacies in a short period.
- Patient agitation when asked to wait for verification.
The pharmacist must verify the prescriber’s DEA registration and whether Hawaii requires the prescriber to hold a Hawaii license or other authorization for a controlled-substance prescription. The pharmacist should also contact the prior Hawaii prescriber and review the PMP pattern. Until those questions are resolved, dispensing would violate the corresponding-responsibility duty. The pharmacist should not fill simply because the patient threatens a complaint.
2. What are the pharmacist’s reporting and documentation obligations if the prescriber cannot be reached and the pharmacist declines to fill?
Read the worked answer
The pharmacist should document the decision and the reason in the pharmacy’s records: the red flags observed, the PMP review, the attempts to contact the prescriber, and the fact that the prescription was not dispensed. The prescription should generally be returned to the patient unless pharmacy policy or Hawaii law requires retention when forgery is suspected.
If the pharmacist suspects forgery, diversion, or doctor shopping, the pharmacist may report the matter to the Hawaii Board of Pharmacy and to law enforcement. HIPAA permits disclosures to law enforcement in limited circumstances, including suspected criminal activity, but the pharmacist should disclose only the minimum necessary information. The pharmacist should avoid accusing the patient publicly and should not make a report that is reckless or defamatory. A report is not a substitute for resolving the clinical and legal red flags; it is a separate obligation that depends on what the pharmacist actually suspects.
3. If the Nevada prescriber later confirms the prescription is legitimate and provides a diagnosis, what must the pharmacist still consider before filling?
Read the worked answer
Prescriber confirmation resolves only one red flag. The pharmacist must still reconcile the early refill and the PMP pattern. A legitimate prescriber confirmation does not automatically authorize an early fill; the pharmacist should ask whether the earlier #90 supply was lost, stolen, or consumed early, and should contact the prior Hawaii prescriber if necessary. If the prescriber authorizes an early refill, the pharmacist should document that authorization and consider whether the quantity should be prorated or the fill delayed to avoid overlapping therapy.
The pharmacist should also verify that the prescriber is authorized to prescribe controlled substances for a patient located in Hawaii, check patient identification, counsel on safe use and disposal, and document the resolution of each red flag. If the PMP still shows unexplained multiple-prescriber activity, the pharmacist may decline to fill even after prescriber confirmation.